Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: A review

Research output: Contribution to journalArticle

Abstract

Amineptine is a tricyclic antidepressant agent with a unique capacity to reduce dopamine uptake selectively in vitro: this effect is also obtained in vivo. In vivo, amineptine increases striatal homovanillic acid without affecting the levels of other metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxytyramine. However, relatively high doses of amineptine preferentially lower the extracellular DOPAC level, assessed by pulse voltammetry, in the nucleus accumbens but not in the striatum. Microdialysis techniques confirm an increase in extracellular dopamine in various brain areas (striatum, nucleus accumbens and frontal cortex) and an increase in extracellular noradrenaline in the frontal cortex and dorsal hippocampus. Chronic treatment with amineptine induces downregulation of dopamine D2, β- and α2-adrenergic receptors. Amineptine enters the brain and its pharmacological effects are probably induced by the unchanged drug, rather than its two main metabolites.

Original languageEnglish
JournalInternational Clinical Psychopharmacology
Volume12
Issue numberSUPPL.3
Publication statusPublished - 1997

    Fingerprint

Keywords

  • Amineptine
  • Antidepressants
  • Dopamine uptake
  • Noradrenaline uptake
  • Receptor downregulation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this